Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Alpine Immune Sciences — Operating income (loss) by Quarter
Alpine Immune Sciences — Operating income (loss) ($M) ($M)
Vertex Pharmaceuticals Alpine Immune Sciences — Operating income (loss): -$22.7M in Q1 2024, up 45.6% from a year earlier. That is the lowest of the 25 quarters on record here. No newer figure appears in the documents we track.
Where the Q1 2024 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001626199 Alpine Immune Sciences).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Alpine Immune Sciences — Operating income (loss) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q1 2024 | Mar 31, 2024 | -22.7 | +45.6% | SEC Filing ↗ |
| Q4 2023 | Dec 31, 2023 | 1.54 | -107.6% | SEC Filing ↗ |
| Q3 2023 | Sep 30, 2023 | -14.6 | +5.2% | SEC Filing ↗ |
| Q2 2023 | Jun 30, 2023 | -15.7 | -5.1% | SEC Filing ↗ |
| Q1 2023 | Mar 31, 2023 | -15.6 | +109.0% | SEC Filing ↗ |
| Q4 2022 | Dec 31, 2022 | -20.4 | +32.4% | SEC Filing ↗ |
| Q3 2022 | Sep 30, 2022 | -13.8 | +4.3% | SEC Filing ↗ |
| Q2 2022 | Jun 30, 2022 | -16.5 | +53.7% | SEC Filing ↗ |
| Q1 2022 | Mar 31, 2022 | -7.46 | -28.9% | SEC Filing ↗ |
| Q4 2021 | Dec 31, 2021 | -15.4 | +137.7% | SEC Filing ↗ |
| Q3 2021 | Sep 30, 2021 | -13.3 | +90.2% | SEC Filing ↗ |
| Q2 2021 | Jun 30, 2021 | -10.7 | +10.1% | SEC Filing ↗ |
| Q1 2021 | Mar 31, 2021 | -10.5 | +88.7% | SEC Filing ↗ |
| Q4 2020 | Dec 31, 2020 | -6.47 | -7.7% | SEC Filing ↗ |
| Q3 2020 | Sep 30, 2020 | -6.97 | -40.5% | SEC Filing ↗ |
| Q2 2020 | Jun 30, 2020 | -9.75 | -19.8% | SEC Filing ↗ |
| Q1 2020 | Mar 31, 2020 | -5.56 | -56.2% | SEC Filing ↗ |
| Q4 2019 | Dec 31, 2019 | -7.01 | -38.8% | SEC Filing ↗ |
| Q3 2019 | Sep 30, 2019 | -11.7 | -5.5% | SEC Filing ↗ |
| Q2 2019 | Jun 30, 2019 | -12.2 | +44.5% | SEC Filing ↗ |
| Q1 2019 | Mar 31, 2019 | -12.7 | +127.6% | SEC Filing ↗ |
| Q4 2018 | Dec 31, 2018 | -11.5 | – | SEC Filing ↗ |
| Q3 2018 | Sep 30, 2018 | -12.4 | – | SEC Filing ↗ |
| Q2 2018 | Jun 30, 2018 | -8.41 | – | SEC Filing ↗ |
| Q1 2018 | Mar 31, 2018 | -5.58 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Alpine Immune Sciences — Operating income (loss) ($M), quarterly Q1 2018–Q1 2024 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/alpine-op-inc
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.